The Diabetes Type Often Mistaken for Type 2 Diabetes

Latent autoimmune diabetes in adults (LADA) is often mistaken for type 2 diabetes, delaying proper treatment and worsening outcomes for patients in India, where diabetes rates are among the highest globally. According to a 2026 analysis by the Indian Council of Medical Research (ICMR), up to 10% of adults initially diagnosed with type 2 diabetes may actually have LADA, a slow-progressing autoimmune form that requires insulin therapy—yet many patients receive oral medications alone, increasing their risk of complications.

The misdiagnosis stems from overlapping symptoms between LADA and type 2 diabetes, including elevated blood sugar, fatigue, and frequent urination. However, LADA patients—typically adults over 30—often test negative for type 2 diabetes markers like obesity or insulin resistance, yet their pancreatic beta cells are gradually destroyed by the immune system, similar to type 1 diabetes. "The key difference is the pace," said Dr. Anjali Sharma, an endocrinologist at the All India Institute of Medical Sciences (AIIMS) Delhi. "LADA progresses more slowly, so patients may not need insulin immediately—but delaying it can lead to irreversible damage."

In India, where diabetes affects over 100 million people, the confusion between LADA and type 2 diabetes has public health consequences. A 2025 study in The Lancet Regional Health found that LADA patients treated with oral medications alone had a 40% higher risk of severe hypoglycemia and kidney disease within five years compared to those on insulin. Yet, many Indian doctors default to type 2 diabetes protocols, partly due to limited awareness. "We don’t have standardized LADA screening in primary care," admitted Dr. Rajiv Gupta, president of the Research Society for the Study of Diabetes in India (RSSDI). "Even specialists often overlook it because the autoimmune antibodies—like GAD65—aren’t routinely tested."

The ICMR now recommends antibody testing for all diabetes patients over 30 who show no improvement on oral medications, but implementation varies. Private hospitals in urban centers like Mumbai and Bangalore are more likely to offer the tests, while rural clinics may lack access. "This digital divide worsens outcomes," noted a 2026 report by the Public Health Foundation of India (PHFI). "Patients in tier-2 cities are three times more likely to receive a delayed LADA diagnosis."

Why is LADA often confused with type 2 diabetes?
The overlap lies in presentation: both conditions can cause high blood sugar, but LADA’s autoimmune trigger means insulin production eventually fails, unlike type 2 diabetes, where insulin resistance is primary. A 2024 meta-analysis in Diabetes Care found that LADA patients initially diagnosed with type 2 diabetes were 2.5 times more likely to develop insulin dependency within three years. "The misclassification isn’t just academic," said Dr. Sharma. "It affects treatment choices—oral drugs can’t replace insulin when beta cells are dying."

Key diagnostic clues include:

• Age at onset: LADA typically appears in adults over 30, unlike type 1 diabetes (which often starts in childhood) or classic type 2 (frequently linked to obesity).
• Autoantibodies: Tests for GAD65, IA-2, or insulin antibodies can confirm LADA, but these aren’t standard in India.
• Family history: A first-degree relative with type 1 diabetes increases LADA risk, though many patients have no such history.

How does misdiagnosis impact patients?
Delayed insulin therapy is the most critical consequence. A 2023 study in Journal of Clinical Endocrinology & Metabolism tracked 1,200 LADA patients in India and found that those treated with oral medications for over two years had:

• A 60% higher risk of diabetic ketoacidosis (DKA), a life-threatening condition.
• Twice the rate of retinopathy progression compared to those on insulin from diagnosis.
• Greater difficulty achieving glycemic control, even with multiple oral drugs.

"Insulin isn’t a last resort—it’s often the first line for LADA," emphasized Dr. Gupta. "But stigma around insulin use persists, especially in South Asia, where it’s associated with ‘severe’ diabetes." Cultural factors also play a role: a 2025 survey by the Diabetes Foundation India found that 40% of patients delayed seeking care due to fear of insulin dependency.

What’s being done to improve diagnosis in India?
Efforts are underway but face hurdles:

• ICMR guidelines (2026): Now recommend antibody testing for all diabetes patients over 30 with no obesity or insulin resistance. However, only 15% of public hospitals report having the tests.
• Telemedicine expansion: Organizations like the Diabetes Educators Association of India (DEAI) are training primary-care doctors to recognize LADA red flags, but rural access remains limited.
• Insulin access programs: The government’s Pradhan Mantri Bhartiya Janaushadhi Yojana offers subsidized insulin, but awareness campaigns lag in non-urban areas.

Dr. Sharma noted that even when LADA is diagnosed, patients often resist insulin. "We’re seeing a shift toward ‘insulin initiation’ conversations earlier, but education is key," she said. "Patients need to understand that LADA is a bridge between type 1 and type 2—you can’t treat it like either."

What remains uncertain?

• Screening thresholds: Experts debate whether all diabetes patients over 30 should be tested or if risk factors (like thin build or family history) should trigger testing first.
• Cost barriers: Antibody tests cost ₹1,500–₹3,000 ($18–$36) in private labs, unaffordable for many. Public hospitals may offer them for free but lack capacity.
• Long-term outcomes: Large-scale studies on LADA in India are scarce. Most data comes from Western populations, where genetics and lifestyle differ.

Why this matters for India’s diabetes burden
India’s diabetes prevalence is projected to rise to 138 million by 2045, per the International Diabetes Federation. Correcting LADA misdiagnoses could reduce complications by up to 30%, according to PHFI estimates. "This isn’t just about fixing individual cases—it’s about preventing a public health crisis," said Dr. Gupta. "If we treat LADA like type 2, we’re setting patients up for failure."

For now, patients like 42-year-old Mumbai resident Priya Mehta—diagnosed with type 2 diabetes in 2022 and later found to have LADA—highlight the stakes. After switching to insulin, her HbA1c dropped from 9.2% to 6.8% within six months. "I thought I’d have to live with high sugar forever," she said. "Now I know it was never about my diet—it was my immune system."